Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Al Bowen Benson, Fengmin Zhao, Neal J. Meropol, Paul J. Catalano, Bapsi Chakravarthy, Patrick J. Flynn, Robert B. Catalano, Bruce J. Giantonio, Edith P. Mitchell, Daniel G. Haller, Cynthia G. Leichman, Nicholas J. Petrelli, Frank A. Sinicrope, Joel E. Tepper, James D. Brierley, Elin R. Sigurdson, Richard M. Whittington, Peter J. O'Dwyer
Institutions: Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Dana-Farber Cancer Institute, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Metro-Minnesota Community Oncology Research Consortium, NRG Oncology, Abramson Cancer Center, University of Pennsylvania, Thomas Jefferson University, Sidney Kimmel Cancer Center, New York University, Mayo Clinic, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Princess Margaret Cancer Centre, Fox Chase Cancer Center, VA New Jersey Health Care System, East Orange VA Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2721631387